Search Results - repurposed

25 Results

Sort By:

Tonabersat as a Neuroprotective Compound for Amyotrophic Lateral Sclerosis

Unmet NeedAmytrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons, and results in muscle atrophy and loss of motor control. ALS affects approximately 17,000 people in the United States and 450,000 worldwide at any given time, and the average life expectancy from diagnosis to mortality is between 2-5 years....

Published: 5/9/2024 | Inventor(s): Nicholas Maragakis

Keywords(s): Amyotrophic Lateral Sclerosis, Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis

Locoregional Chemotherapy for Liver Cancers

Unmet NeedOver 800,000 people are diagnosed with liver cancer annually. As the leading cause of cancer death worldwide, liver cancer accounts for more than 700,000 deaths annually. Recently, Johns Hopkins researchers have developed new chemotherapeutic drugs to treat liver cancer that demonstrate higher efficacy than the current standard of care for...

Published: 5/9/2024 | Inventor(s): Florin Selaru, Ling Li

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Drug Delivery Mechanism, Liver Cancer, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Liver Cancer

Discovery of Novel Compounds that Enhance Enteric Nervous System Function

Unmet needNecrotizing enterocolitis (NEC), a condition of newborns in which a portion of the bowel dies. NEC affects one in 1000-4000 births, or about 10% of preterm children and is associated with an overall mortality of up to 40%. NEC is thought to be caused by defective bacterial-host signaling during colonization of the intestine with bacteria,...

Published: 5/9/2024 | Inventor(s): David Hackam, Peng Lu, Chhinder Sodhi

Keywords(s): Agonists/Promoters, Disease Indication, Inflammatory Disorders, Necrotizing Enterocolitis (NEC), Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Alpha particle formulations for treatment of solid tumors

Unmet NeedHepatocellular carcinoma (HCC) is the fifth most common cancer type worldwide and a leading cause of cancer related deaths. HCC is clinically silent in its early stages, leading to diagnosis at more advanced stages when only non-surgical, palliative treatment is available. One treatment option for advanced HCC is intra-arterial therapy and...

Published: 5/9/2024 | Inventor(s): Jessie Nedrow, Eleni Liapi

Keywords(s): Biologics, Cancers, Disease Indication, Liver Cancer, Non-novel, Predicted Novelty, Radioisotope Therapy, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Oncology > Liver Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

Metipranolol for Treatment of Retinitis Pigmentosa

Unmet NeedRetinitis pigmentosa (RP) is a genetic disorder with a prevalence of 1 in 4000 people worldwide. RP can be the result of a number of mutations that all result in severe rod photoreceptor degeneration and death, causing excess oxygen in the outer retina and subsequent oxidative damage to cone photoreceptors. Symptom onset begins in childhood...

Published: 5/9/2024 | Inventor(s): Peter Campochiaro, Yogita Kanan, Ken Green

Keywords(s): Antagonists/Inhibitors, Disease Indication, Eye Disorders, Macular Degeneration, Non-novel, Predicted Novelty, Repurposed, Retinitis pigmentosa, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Ophthalmology > Retinitis Pigmentosa, Clinical and Disease Specializations > Ophthalmology > Macular Degeneration, Technology Classifications > Therapeutic Modalities > Small Molecules

A Combination of Carbapenem and Avibactam for Treatment of Bacterial Infections

UNMET NEEDMultidrug-resistant (MDR) pathogens, e.g. Mycobacterium tuberculosis (TB) are a growing threat with significant economic ramifications. In particular, TB is one of the top 10 causes of death worldwide, with an estimated 10.4 million people infected, globally. An estimated 1.8 million deaths are attributable to TB. MDR-TB is TB that does not...

Published: 5/9/2024 | Inventor(s): Gyanu Lamichhane

Keywords(s): Antagonists/Inhibitors, Bacterial Infections, Combination, Disease Indication, Infectious Diseases, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections

Glutamine Antagonists for the Treatment of Cognitive Deficits, including NeuroAIDs

Some glutamine antagonists have been shown to have anti-cancer activities in multiple preclinical and clinical studies. However the toxicity of the glutamine antagonists at doses necessary for their anticancer effects have hampered their clinical development. Herein we describe a completely novel use for the glutamine antagonists. Using a prototype...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, David Volsky, Kristen Hollinger, Michael Nedelcovych, Atsushi Kamiya

Keywords(s): Antagonists/Inhibitors, CNS and Neurological Disorders, Cognitive Impairment, Disease Indication, HIV/AIDS, HIV-Associated Neurocognitive Disorders, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Clinical and Disease Specializations > Neurology > Cognitive Impairment, Clinical and Disease Specializations > Neurology > HIV-Associated Neurocognitive Disorders, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities

Acriflavine Biodegradable CCP:SA Polymers for the Treatment of Malignant Glioma

We investigated the efficacy of the intracranial delivery of a promising anti-cancer drug, whose use has not yet been described for the treatment of malignant glioma. The drug is a trypanocidal, antibacterial, antiviral agent mostly used in cases of sleeping sickness and wound healing. It has demonstrated highly effective antitumor activity against...

Published: 5/9/2024 | Inventor(s): Betty Tyler, Antonella Mangraviti, Henry Brem, Alessandro Olivi, Tula Raghavan

Keywords(s): Brain Cancer, Cancers, Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Glioma, Non-novel, Polymers, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Membrane Active Chelators (MACs) as Chemotherapueutic Agents for Treatment of Human African Trypanosomiasis (HAT)

Membrane Activated Chelators (MACs) are proprietary neuroprotective drugs [D-PHARM LTD; Rehovot Isreal] that modulate cell membrane metal ion homeostasis by adopting an inactive conformation outside only in the lipid environment of cell membranes. In this environment, the drugs are able to unable to bind metal ions at their elevated non-physiological...

Published: 5/9/2024 | Inventor(s): Dennis Grab

Keywords(s): Antagonists/Inhibitors, Chemotherapy, Disease Indication, Human African Trypanosomiasis, Human African Trypanosomiasis (HAT), Infectious Diseases, Non-novel, Parasitic Infections, Predicted Novelty, Repurposed, Single, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Human African Trypanosomiasis, Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities

Buccal and Intranasal Delivery of Fospropofol

INVENTION NOVELTY This invention provides for novel formulations and delivery methods of the propofol prodrug, fospropofol, allowing for its use in additional indications beyond anesthesia, including migraine, analgesia, and emesis treatment. VALUE PROPOSITION Propofol and its water soluble prodrug, fospropofol, are short-acting anesthetics used...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, Rana Rais, James Vornov

Keywords(s): Chronic Pain, CNS and Neurological Disorders, Disease Indication, Migraine, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Migraine, Clinical and Disease Specializations > Pain, Clinical and Disease Specializations > Pain > Chronic Pain, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

1 2 3